LONA LeonaBio, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1620463 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-313.6%
TTM EPS YoY-129.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-729.0%
ROA-457.7%
ROIC (approx.)-3,861.7%
Asset turnover—
Leverage & solvency
Liabilities / assets58.0%
Debt / equity0.00x
Current ratio4.96x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.49x
Accruals ratio-234.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $17.50M | $70.68M | $93.79M | $61.46M | $42.79M |
| SG&A expense | $16.68M | $26.09M | $33.30M | $32.55M | $21.23M |
| Operating income | -$102.27M | -$100.90M | -$125.47M | -$104.02M | -$64.02M |
| Interest expense | — | — | — | — | $3,000 |
| Pretax income | -$105.61M | -$96.91M | -$117.44M | -$95.78M | -$54.96M |
| Income tax | $0 | — | — | — | — |
| Net income | -$105.61M | -$96.94M | -$117.67M | -$95.64M | -$54.85M |
| EBITDA | -$101.29M | -$99.93M | -$124.50M | -$103.17M | -$63.54M |
| EPS (basic) | -24.70 | -25.19 | -3.09 | -2.53 | -1.49 |
| EPS (diluted) | -24.70 | -25.19 | -3.09 | -2.53 | -1.49 |
| Weighted avg. shares (diluted) | 4.28M | 3.85M | 38.02M | 37.73M | 36.92M |
| Balance sheet | |||||
| Cash & equivalents | $69.28M | $48.44M | $90.58M | $95.97M | $110.54M |
| Short-term investments | $19.05M | $2.84M | $56.84M | $104.38M | $143.22M |
| Current assets | $89.46M | $54.84M | $154.73M | $207.53M | $260.80M |
| PP&E, net | $1.47M | $2.44M | $3.39M | $4.05M | $3.76M |
| Total assets | $92.15M | $58.78M | $160.25M | $258.15M | $332.01M |
| Current liabilities | $47.50M | $13.13M | $28.84M | $21.43M | $9.29M |
| Total liabilities | $64.36M | $13.94M | $30.06M | $23.02M | $10.92M |
| Shareholders' equity | $27.79M | $44.84M | $130.19M | $235.14M | $321.08M |
| Shares outstanding | 9.34M | 3.90M | 38.17M | 37.88M | 37.38M |
| Cash flow statement | |||||
| Operating cash flow | -$45.73M | -$97.17M | -$100.75M | -$72.47M | -$43.10M |
| Capital expenditure | — | $33,000 | $304,000 | $1.14M | $1.57M |
| Free cash flow | — | -$97.20M | -$101.06M | -$73.61M | -$44.67M |
| Investing cash flow | -$15.89M | $54.83M | $95.09M | $57.66M | -$4.08M |
| Financing cash flow | $82.46M | $194,000 | $493,000 | $654,000 | $97.09M |
| Depreciation & amortization | $972,000 | $970,000 | $969,000 | $845,000 | $479,000 |
| Stock-based compensation | $6.10M | $11.05M | $10.62M | $10.61M | $4.62M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.